J&J and its co-defendants were ordered to pay $25.75 million in damages in the company's latest talc defeat, wrapped up in court Thursday.

Pfizer, which has struggled with manufacturing issues that have kept it from producing essential injected narcotics, says shipments have resumed.

The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.

J&J says Zytiga won't face generics this year, but Sun just won FDA approval for its branded copy, a tweak on the big seller's active ingredient.

Merck already controls a big piece of the first-line non-small cell lung cancer market, and it likely just secured most of the rest.

As U.S. tax reform is expected to more than halve its 2018 tax rate, AbbVie has said it will make $350 million in charitable contributions in 2018.

AveXis, the gene therapy biotech Novartis snapped up for $8.7 billion, will build a new manufacturing plant to produce its specialized therapies.

Johnson & Johnson opened a window into its eye health portfolio this week with the debut of a new corporate site.

Social media can be scary. But Alimera Sciences is convinced that with fastidious prep—and plenty of it—pharma companies should have nothing to fear.